Conspicuous Response to Direct-Acting Antivirals in Chronic Hepatitis C-related Immune Thrombocytopenia: A Case Report

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2022 May 20

PMID 35592216

Authors

Tsung-Lung Tsai

Huei-Min Jhou

Frank S Fan

Affiliations

Soon will be listed here.

Abstract

A 39-year-old man with a history of intravenous drug use was diagnosed to have a sudden onset of immune thrombocytopenia (ITP) in the background of a chronic hepatitis C infection with genotype 3a. Two courses of high-dose pulse dexamethasone therapy (40 mg daily for consecutive four days) failed to raise the platelet counts, but a combination direct-acting antiviral (DAA) regimen of sofosbuvir and velpatasvir, which had been proved to be effective for all hepatitis C virus (HCV) genotypes, successfully restored the platelets number to normal ranges after hepatitis C virus ribonucleic acid (RNA) was totally eliminated. Molecular mimicry of hepatitis C virus envelope proteins with platelet surface antigens is proposed to be the underlying cause of immune thrombocytopenia. An adequate direct-acting antiviral regimen is considered to be the most reliable therapy for hepatitis C-related immune thrombocytopenia.

References

Alcazer V, Miailhes P, Ramiere C, Charre C, Cotte L . Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia - a case report. BMC Infect Dis. 2018; 18(1):682. PMC: 6300032. DOI: 10.1186/s12879-018-3597-4. View

Lebano R, Rosato V, Masarone M, Romano M, Persico M . The effect of antiviral therapy on hepatitis C virus-related thrombocytopenia: a case report. BMC Res Notes. 2014; 7:59. PMC: 3915622. DOI: 10.1186/1756-0500-7-59. View

Dahal S, Upadhyay S, Banjade R, Dhakal P, Khanal N, Bhatt V . Thrombocytopenia in Patients with Chronic Hepatitis C Virus Infection. Mediterr J Hematol Infect Dis. 2017; 9(1):e2017019. PMC: 5333732. DOI: 10.4084/MJHID.2017.019. View

Wang X, Wei L . Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China. J Clin Transl Hepatol. 2021; 9(3):419-427. PMC: 8237141. DOI: 10.14218/JCTH.2020.00097. View

Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C . Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016; 22(34):7824-40. PMC: 5016383. DOI: 10.3748/wjg.v22.i34.7824. View

Asselah T, Marcellin P, Schinazi R . Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?. Liver Int. 2018; 38 Suppl 1:7-13. PMC: 7713514. DOI: 10.1111/liv.13673. View

Chen Y, Tseng C, Tseng K . Rapid platelet count improvement in chronic hepatitis C patients with thrombocytopenia receiving direct-acting antiviral agents. Medicine (Baltimore). 2020; 99(19):e20156. PMC: 7220127. DOI: 10.1097/MD.0000000000020156. View

Ruta S, Cernescu C . Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World J Gastroenterol. 2015; 21(38):10811-23. PMC: 4600582. DOI: 10.3748/wjg.v21.i38.10811. View

Chiao E, Engels E, Kramer J, Pietz K, Henderson L, Giordano T . Risk of immune thrombocytopenic purpura and autoimmune hemolytic anemia among 120 908 US veterans with hepatitis C virus infection. Arch Intern Med. 2009; 169(4):357-63. PMC: 2782638. DOI: 10.1001/archinternmed.2008.576. View

10.

Preciado M, Valva P, Escobar-Gutierrez A, Rahal P, Ruiz-Tovar K, Yamasaki L . Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy. World J Gastroenterol. 2014; 20(43):15992-6013. PMC: 4239486. DOI: 10.3748/wjg.v20.i43.15992. View

11.

Zhang W, Nardi M, Borkowsky W, Li Z, Karpatkin S . Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood. 2008; 113(17):4086-93. PMC: 2673130. DOI: 10.1182/blood-2008-09-181073. View

12.

Chan A, Patel K, Naggie S . Genotype 3 Infection: The Last Stand of Hepatitis C Virus. Drugs. 2017; 77(2):131-144. PMC: 5726887. DOI: 10.1007/s40265-016-0685-x. View

13.

Singh A, Uzun G, Bakchoul T . Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management. J Clin Med. 2021; 10(4). PMC: 7920457. DOI: 10.3390/jcm10040789. View

14.

Cooper N, Ghanima W . Immune Thrombocytopenia. N Engl J Med. 2019; 381(10):945-955. DOI: 10.1056/NEJMcp1810479. View

15.

Attar B, Van Thiel D . Hepatitis C virus: A time for decisions. Who should be treated and when?. World J Gastrointest Pharmacol Ther. 2016; 7(1):33-40. PMC: 4734952. DOI: 10.4292/wjgpt.v7.i1.33. View

16.

Li G, De Clercq E . Current therapy for chronic hepatitis C: The role of direct-acting antivirals. Antiviral Res. 2017; 142:83-122. PMC: 7172984. DOI: 10.1016/j.antiviral.2017.02.014. View

17.

van der Meer A, Maan R, Veldt B, Feld J, Wedemeyer H, Dufour J . Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. J Gastroenterol Hepatol. 2015; 31(6):1168-76. DOI: 10.1111/jgh.13252. View

18.

Segna D, Dufour J . Other Extrahepatic Manifestations of Hepatitis C Virus Infection (Pulmonary, Idiopathic Thrombocytopenic Purpura, Nondiabetes Endocrine Disorders). Clin Liver Dis. 2017; 21(3):607-629. DOI: 10.1016/j.cld.2017.03.014. View

19.

Khan S, Soni S, Veerapu N . HCV Replicon Systems: Workhorses of Drug Discovery and Resistance. Front Cell Infect Microbiol. 2020; 10:325. PMC: 7344236. DOI: 10.3389/fcimb.2020.00325. View

20.

Johira Y, Hatooka H, Mori N, Fukuhara T, Takaki S, Shimomura Y . Regression of Idiopathic Thrombocytopenic Purpura in a Patient With Eradication of Hepatitis C Virus by Direct-Acting Antivirals. Hepatology. 2019; 71(1):389-391. DOI: 10.1002/hep.30900. View